



August 2, 2012

Patrick McLaughlin
Executive Director
Anaheim Clinical Trials
1085 N. Harbor Blvd.
Anaheim, CA 92801

Re: GS-US-196-0103

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection

Dear Mr. McLaughlin,

This letter serves as PPD and Gilead's appreciation for your study participation. Dr. Michael DeMicco at Anaheim Clinical Trials, LLC has served as Principal Investigator since August 2008. Dr. DeMicco and Michelle Haynes, CCRC, Certified Clinical Research Coordinator has shown extreme diligence with following their active patients.

They have randomized 17 patients into the study and have done an excellent job with continuing the SVR Substudy for the protocol with 7 eligible patients who met the eligibility criteria.

Michelle has met all study timelines and proactively contacts the patients prior to their study visit to ensure compliance. Michelle has always been on time and available for all monthly site management contacts as well as yearly on-site monitoring visits during the study.

We greatly appreciate their study participation and look forward to working with their site with other studies in the future.

Kind regards,

Margo Walker, BS, LVT
PPD Senior Clinical Research Associate (SrCRA)

cc: Crissie Hoelzle, PPD Clinical Team Manager (CTM)
cc: Sunita Swamy, Gilead Sciences, Clinical Research Associate